X

Trial Profile

A Phase I Study of Trabectedin in Combination With Fixed Doses of Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 22 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin (Primary) ; Olaratumab (Primary) ; Trabectedin (Primary)
Indications Leiomyosarcoma
Focus Adverse reactions

Most Recent Events

14 Mar 2019 Planned End Date changed from 1 Oct 2022 to 1 Jun 2023.
14 Mar 2019 Planned primary completion date changed from 1 Oct 2020 to 1 Jun 2021.
14 Mar 2019 Planned initiation date changed from 1 Oct 2018 to 1 Jun 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com